Related Experiment Video
Updated: Aug 24, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
Probing predilection to Crohn's disease and Crohn's disease flares: A crowd-sourced bioinformatics approach
Jihad Aljabban1, Michael Rohr2, Vincent J Borkowski1,1
1University of Wisconsin Hospitals and Clinics, Madison, WI, United States.
Insights
This study reveals key molecular pathways and gene expression changes in Crohn's Disease (CD) by comparing active and inactive lesions. Findings highlight immune and metabolic dysregulation, offering potential therapeutic targets for this inflammatory bowel disease.
Area of Science:
- Gastroenterology
- Immunology
- Molecular Biology
Background:
- Crohn's Disease (CD) is a chronic gastrointestinal inflammatory condition impacting millions globally.
- Despite advancements in biologic therapies like anti-TNF drugs, CD remains a significant health burden with unmet treatment needs.
Purpose of the Study:
- To investigate molecular differences between active and inactive CD lesions using meta-analysis.
- To identify novel therapeutic targets by analyzing gene expression patterns in colonic biopsies.
Main Methods:
- Two meta-analyses were performed on Gene Expression Omnibus data using the STARGEO platform.
- Colonic biopsies from active CD, inactive CD, and healthy controls were analyzed.
- Ingenuity Pathway Analysis (IPA) was employed to interpret differential gene expression.
Main Results:
- Inactive CD showed activation of FXR/RXR, LXR/RXR, citrulline metabolism, and atherosclerosis pathways, with upstream regulators in innate immunity and sterol regulation.
- Active CD lesions exhibited pathways related to immune cell adhesion, fibrosis, and inflammation, with upstream regulators including LPS, TNF, and IL1B.
- Upregulated genes in active CD are involved in immune response, while downregulated genes relate to cellular metabolism and transport.
Conclusions:
- The study identifies distinct molecular signatures differentiating active and inactive Crohn's Disease.
- The findings provide insights into immune and metabolic alterations in CD, suggesting potential therapeutic strategies.
- The STARGEO platform facilitates disease investigation and the discovery of new treatment avenues.
Background:
Crohn's Disease (CD) is an inflammatory disease of the gastrointestinal tract that affects millions of patients. While great strides have been made in treatment, namely in biologic therapy such as anti-TNF drugs, CD remains a significant health burden.
Method:
We conducted two meta-analyses using our STARGEO platform to tag samples from Gene Expression Omnibus. One analysis compares inactive colonic biopsies from CD patients to colonic biopsies from healthy patients as a control and the other compares colonic biopsies from active CD lesions to inactive lesions. Separate tags were created to tag colonic samples from inflamed biopsies (total of 65 samples) and quiescent tissue in CD patients (total of 39 samples), and healthy tissue from non-CD patients (total of 30 samples). Results from the two meta-analyses were analyzed using Ingenuity Pathway Analysis.
Results:
For the inactive CD vs healthy tissue analysis, we noted FXR/RXR and LXR/RXR activation, superpathway of citrulline metabolism, and atherosclerosis signaling as top canonical pathways. The top upstream regulators include genes implicated in innate immunity, such as TLR3 and HNRNPA2B1, and sterol regulation through SREBF2. In addition, the sterol regulator SREBF2, lipid metabolism was the top disease network identified in IPA (Fig. 1). Top upregulated genes hold implications in innate immunity (DUOX2, REG1A/1B/3A) and cellular transport and absorption (ABCG5, NPC1L1, FOLH1, and SLC6A14). Top downregulated genes largely held roles in cell adhesion and integrity, including claudin 8, PAQR5, and PRKACB.For the active vs inactive CD analysis, we found immune cell adhesion and diapedesis, hepatic fibrosis/hepatic stellate cell activation, LPS/IL-1 inhibition of RXR function, and atherosclerosis as top canonical pathways. Top upstream regulators included inflammatory mediators LPS, TNF, IL1B, and TGFB1. Top upregulated genes function in the immune response such as IL6, CXCL1, CXCR2, MMP1/7/12, and PTGS2. Downregulated genes dealt with cellular metabolism and transport such as CPO, RBP2, G6PC, PCK1, GSTA1, and MEP1B.
Conclusion:
Our results build off established and recently described research in the field of CD. We demonstrate the use of our user-friendly platform, STARGEO, in investigating disease and finding therapeutic avenues.
More Related Videos
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
15:17Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...